The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multi-institutional experience using 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) in patients with pancreatic cancer (PCA).
Priscila Hermont Goncalves
No relevant relationships to disclose
Joshua Michael Ruch
No relevant relationships to disclose
Jennifer Byer
No relevant relationships to disclose
Anthony Frank Shields
No relevant relationships to disclose
Minsig Choi
No relevant relationships to disclose
Richard D. Kim
No relevant relationships to disclose
Mark M. Zalupski
No relevant relationships to disclose
Philip Agop Philip
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi